# Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

> **NCT02975206** · PHASE2 · COMPLETED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 484 (actual)

## Conditions studied

- Pruritus
- Atopic Dermatitis

## Interventions

- **DRUG:** Serlopitant High Dose
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Serlopitant Low Dose

## Key facts

- **NCT ID:** NCT02975206
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-02-23
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975206, "Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02975206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*